Obestatin induced recovery of myocardial dysfunction in type 1 diabetic rats: Underlying mechanisms

Cardiovascular Diabetology

Volumn 11, Issue , 2012, Pages

  Aragno, Manuela ^a   Mastrocola, Raffaella ^a   Ghé, Corrado ^a   Arnoletti, Elisa ^a   Bassino, Eleonora ^a   Alloatti, Giuseppe ^a   Muccioli, Giampiero ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Cardiac dysfunction; Cell survival kinases; Diabetes; Obestatin; Oxidative unbalance; Pro fibrogenic and inflammatory factors

Indexed keywords

BETA 1 ADRENERGIC RECEPTOR; GLYCOGEN SYNTHASE KINASE 3BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MYOSIN HEAVY CHAIN ALPHA; OBESTATIN; PROTEIN KINASE B; REACTIVE OXYGEN METABOLITE; TUMOR NECROSIS FACTOR ALPHA;

ADRENERGIC SYSTEM; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; CONVALESCENCE; EMBRYO; ENZYME PHOSPHORYLATION; HEART DISEASE; HEART MUSCLE CONTRACTILITY; HEART PAPILLARY MUSCLE; HYPERGLYCEMIA; HYPERLIPIDEMIA; INSULIN DEPENDENT DIABETES MELLITUS; MALE; NONHUMAN; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STREPTOZOCIN DIABETES; TREATMENT DURATION; UPREGULATION; WESTERN BLOTTING;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; BLOTTING, WESTERN; CARDIOTONIC AGENTS; CELL LINE; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; GLYCOGEN SYNTHASE KINASE 3; HEART DISEASES; HYPOGLYCEMIC AGENTS; INFLAMMATION MEDIATORS; MALE; METFORMIN; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MYOCARDIAL CONTRACTION; MYOSIN HEAVY CHAINS; NF-KAPPA B; OXIDATIVE STRESS; PAPILLARY MUSCLES; PEPTIDE HORMONES; PHOSPHORYLATION; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RATS, WISTAR; RECEPTORS, ADRENERGIC, BETA-1; RECOVERY OF FUNCTION; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA; VENTRICULAR MYOSINS;

EID: 84867338438     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-11-129     Document Type: Article

References (54)

1. Pemberton C, Richards AM. Biochemistry of ghrelin precursor peptides. Vitam Horm 2008, 77:13-30.
2. Ren AJ, Guo ZF, Wang YK, Lin L, Zheng X, Yuan WJ. Obestatin, obesity and diabetes. Peptides 2009, 30:439-444. 10.1016/j.peptides.2008.10.002, 18992781.
3. Tang SQ, Jiang QY, Zhang YL, Zhu XT, Shu G, Gao P, Feng DY, Wang XQ, Dong XY. Obestatin: its physicochemical characteristics and physiological functions. Peptides 2008, 29:639-645. 10.1016/j.peptides.2008.01.012, 18325633.
4. Zhang JV, Ren PG, Avsian-Kretchmer O, Luo CW, Rauch R, Klein C, Hsueh AJW. Obestatin, a peptide encoded by the ghrelin gene, opposes ghrelin's effects on food intake. Science 2005, 310:996-999. 10.1126/science.1117255, 16284174.
5. Gourcerol H, Tache Y. Obestatin - a ghrelin associated peptide that does not hold its promise to suppress food intake and motility. Neurogastrenterol Motil 2007, 19:161-165.
6. Mondal MS, Toshinai K, Ueno H, Koshinaka K, Nakazato M. Characterization of obestatin in rat and human stomach and plasma and its lack of acute effect on feeding behaviour in rodents. J Endocrinol 2008, 198:339-346. 10.1677/JOE-08-0082, 18480381.
7. Seoane LM, Al-Massadi O, Pazos Y, Pagotto U, Casanueva FF. Central obestatin administration does not modify either spontaneous or ghrelin-induced food intake in rats. J Endocrinol Invest 2006, 29:RC13-15.
8. Holst B, Egerod KL, Schild E, Vickers SP, Cheetham S, Gerlach LO, Storjohann L, Stidsen CE, Jones R, Beck-Sickinger AG, Schwartz TW. GPR39 signaling is stimulated by zinc ions but not by obestatin. Endocrinology 2007, 148:13-20.
9. Lauwers E, Landuyt B, Arckens L, Schoofs L, Luyten W. Obestatin does not activate orphan G protein-coupled receptor GPR39. Biochem Biophys Res Commun 2006, 351:21-25. 10.1016/j.bbrc.2006.09.141, 17054911.
10. Granata R, Settanni F, Gallo D, Trovato L, Biancone L, Cantaluppi V, Nano R, Annunziata M, Campiglia P, Arnoletti E, Ghè C, Volante M, Papotti M, Muccioli G, Ghigo E. Obestatin promotes survival of pancreatic β-cells and human islets and induces expression of genes involved in the regulation of β-cell mass and function. Diabetes 2008, 57:967-79. 10.2337/db07-1104, 18162507.
11. Granata R, Volante M, Settanni F, Gauna C, Ghé C, Annunziata M, Deidda B, Gesmundo I, Abribat T, van der Lely AJ, Muccioli G, Ghigo E, Papotti M. Unacylated ghrelin and obestatin increase islet cell mass and prevent diabetes in streptozotocin-treated newborn rats. J Mol Endocrinol 2010, 45:9-17. 10.1677/JME-09-0141, 20382773.
12. Granata R, Settanni F, Julien M, Nano R, Togliatto G, Trombetta A, Gallo D, Piemonti L, Brizzi MF, Abribat T, van Der Lely AJ, Ghigo E. Des-Acyl Ghrelin Fragments and Analogues Promote Survival of Pancreatic β-Cells and Human Pancreatic Islets and Prevent Diabetes in Streptozotocin-Treated Rats. J Med Chem 2012, 55:2585-96. 10.1021/jm201223m, 22352743.
13. Irako T, Akamizu T, Hosoda H, Iwakura H, Ariyasu H, Tojo K, Tajima N, Kangawa K. Ghrelin prevents development of diabetes at adult age in streptozotocin-treated newborn rats. Diabetologia 2006, 49(6):1264-73. 10.1007/s00125-006-0226-3, 16570155.
14. Ozbay Y, Aydin S, Dagli AF, Akbulut M, Dagli N, Kilic N, Rahman A, Sahin I, Polat V, Ozercan HI, Arslan N, Sensoy D. Obestatin is present in saliva: alterations in obestatin and ghrelin levels of saliva and serum in ischemic heart disease. BMB Rep 2008, 41:55-61. 10.5483/BMBRep.2008.41.1.055, 18304451.
15. Huda MS, Durham BH, Wong SP, Deepak D, Kerrigan D, McCulloch P, Ranganath L, Pinkney J, Wilding JP. Plasma obestatin levels are lower in obese and post-gastrectomy subjects, but do not change in response to a meal. Int J Obes (Lond) 2008, 32:129-135.
16. Xin X, Ren AJ, Zheng X, Qin YW, Zhao XX, Yuan WJ, Guo ZF. Disturbance of circulating ghrelin and obestatin in chronic heart failure patients especially in those with cachexia. Peptides 2009, 30:2281-2285. 10.1016/j.peptides.2009.07.026, 19666068.
17. Li ZF, Guo ZF, Cao J, Hu JQ, Zhao XX, Xu RL, Huang XM, Qin YW, Zheng X. Plasma ghrelin and obestatin levels are increased in spontaneously hypertensive rats. Peptides 2010, 31:297-300. 10.1016/j.peptides.2009.11.018, 19944125.
18. Alloatti G, Arnoletti E, Bassino E, Penna C, Perrelli MG, Ghe C, Muccioli G. Obestatin affords cardioprotection to the ischemic-reperfused isolated rat heart and inhibits apoptosis in cultures of similarly stressed cardiomyocytes. Am J Physiol Heart Circ Physiol 2010, 299:H470-481. 10.1152/ajpheart.00800.2009, 20525876.
19. Asbun J, Villarreal FJ. The pathogenesis of myocardial fibrosis in the setting of diabetic cardiomyopathy. J Am Coll Cardiol 2006, 47:693-700. 10.1016/j.jacc.2005.09.050, 16487830.
20. Avogaro A, de Kreutzenberg SV, Fadini GP. Oxidative stress and vascular disease in diabetes: is the dichotomization of insulin signaling still valid?. Free Radic Biol Med 2008, 44:1209-1215. 10.1016/j.freeradbiomed.2007.12.021, 18191647.
21. Baldanzi G, Filigheddu N, Cutrupi S, Catapano F, Bonissoni S, Fubini A, Malan D, Baj G, Granata R, Broglio F, Papotti M, Surico N, Bussolino F, Isgaard J, Deghenghi R, Sinigaglia F, Prat M, Muccioli G, Ghigo E, Graziani A. Ghrelin and des-acyl ghrelin inhibit cell death in cardiomyocytes and endothelial cells through ERK1/2 and PI 3-kinase/Akt. J Cell Biol 2002, 159:1029-1037. 10.1083/jcb.200207165, 2173981, 12486113.
22. Fonarow GC, Srikanthan P. Diabetic cardiomyopathy. Endocrinol Metab Clin North Am 2006, 35:575-599. 10.1016/j.ecl.2006.05.003, 16959587.
23. Maiese K, Chong ZZ, Shang YC. Mechanistic insights into diabetes mellitus and oxidative stress. Curr Med Chem 2007, 14:1729-1738. 10.2174/092986707781058968, 2447161, 17627510.
24. Zou MH, Kirkpatrick SS, Davis BJ, Nelson JS, Wiles WG, Schlattner U, Neumann D, Brownlee M, Freeman MB, Goldman MH. Activation of the AMP-activated protein kinase by the anti-diabetic drug metformin in vivo. Role of mitochondrial reactive nitrogen species. J Biol Chem 2004, 279(42):43940-51. 10.1074/jbc.M404421200, 15265871.
25. Kola B, Hubina E, Tucci SA, Kirkham TC, Garcia EA, Mitchell SE, Williams LM, Hawley SA, Hardie DG, Grossman AB, Korbonits M. Cannabinoids and ghrelin have both central and peripheral metabolic and cardiac effects via AMP-activated protein kinase. J Biol Chem 2005, 280:25196-25201. 10.1074/jbc.C500175200, 15899896.
26. Ravindranath V. Animal models and molecular markers for cerebral ischemia-reperfusion injury in brain 1994, 610-619. New York: Academic Press, 233, Methods in Enzymology.
27. Owens CWI, Belcher RV. A colorimetric micro-method for the determination of glutathione. Biochem J 1965, 94:705-711. 1206606, 14340062.
28. Muccioli G, Baragli A, Granata R, Papotti M, Ghigo E. Heterogeneity of ghrelin/growth hormone secretagogue receptors. Toward the understanding of the molecular identity of novel ghrelin/GHS receptors. Neuroendocrinology 2007, 86:147-164. 10.1159/000105141, 17622734.
29. Aragno M, Mastrocola R, Alloatti G, Vercellinatto I, Bardini P, Geuna S, Catalano MG, Danni O, Boccuzzi G. Oxidative stress triggers cardiac fibrosis in the heart of diabetic rats. Endocrinology 2008, 149:380-388.
30. Gando S, Hattori Y, Akaishi Y, Nishihira J, Kanno M. Impaired contractile response to β adrenoceptor stimulation in diabetic rat hearts: alterations in β adrenoceptors-G protein-adenylate cyclase system and phospholamban phosphorylation. J Pharmacol Exp Ther 1997, 282:475-84.
31. Steinberg GR, Kemp BE. AMPK in Health and Disease. Physiol Rev 2009, 89:1025-1078. 10.1152/physrev.00011.2008, 19584320.
32. Soares JB, Leite-Moreira AF. Ghrelin, des-acyl ghrelin and obestatin: Three pieces of the same puzzle. Peptides 2008, 29:1255-1270. 10.1016/j.peptides.2008.02.018, 18396350.
33. Granata R, Isgaard J, Alloatti G, Ghigo E. Cardiovascular actions of ghrelin and growth hormone-releasing hormone. Exp Biol Med 2011, 236:505-514.
34. El Eter E, Al Tuwaijiri A, Hagar H, Arafa M. In vivo and in vitro antioxidant activity of ghrelin: attenuation of gastric ischemic injury in the rat. J Gastroenterol Hepatol 2007, 22:1791-1799. 10.1111/j.1440-1746.2006.04696.x, 17914952.
35. Zhao H, Liu G, Wang Q, Ding L, Cai H, Jiang H, Xin Z. Effect of ghrelin on human endothelial cells apoptosis induced by high glucose. Biochem Biophys Res Commun 2007, 362:677-681. 10.1016/j.bbrc.2007.08.021, 17719561.
36. Paravicini TM, Touyz RM. NADPH oxidases, reactive oxygen species, and hypertension: clinical implications and therapeutic possibilities. Diabetes Care 2008, 31(2):S170-180. 10.2337/dc08-s247, 18227481.
37. Sanada S, Komuro I, Kitakaze M. Pathophysiology of myocardial reperfusion injury: preconditioning, postconditioning, and translational aspects of protective measures. Am J Physiol Heart Circ Physiol 2011, 301:H1723-41. 10.1152/ajpheart.00553.2011, 21856909.
38. Kyoraku I, Shiomi K, Kangawa K, Nakazato M. Ghrelin reverses experimental diabetic neuropathy in mice. Biochem Biophys Res Commun 2009, 389:405-408. 10.1016/j.bbrc.2009.08.171, 19733151.
39. Hussein AA, Abdel-Aziz A, Gabr M, Hemmaid KZ. Myocardial and metabolic dysfunction in type 2 diabetic rats: impact of ghrelin. Can J Physiol Pharmacol 2012, 90:99-111. 10.1139/y11-103, 22188509.
40. Roe ND, Thomas DP, Ren J. Inhibition of NADPH oxidase alleviates experimental diabetes-induced myocardial contractile dysfunction. Diabetes Obes Metab 2011, 13:465-73. 10.1111/j.1463-1326.2011.01369.x, 21272185.
41. Paiva MA, Gonçalves LM, Providência LA, Davidson SM, Yellon DM, Mocanu MM. Transitory activation of AMPK at reperfusion protects the ischaemic-reperfused rat myocardium against infarction. Cardiovasc Drugs Ther 2010, 24:25-32. 10.1007/s10557-010-6222-3, 2874156, 20229055.
42. Young LH. AMP-activated protein kinase conducts the ischemic stress response orchestra. Circulation 2008, 117:832-840. 10.1161/CIRCULATIONAHA.107.713115, 18268160.
43. Nakamura K, Kusuoka H, Ambrosio G, Becker LC. Glycolysis is necessary to preserve myocardial Ca2+ homeostasis during beta-adrenergic stimulation. Am J Physiol 1993, 264:H670-H678.
44. Jeremy RW, Ambrosio G, Pike MM, Jacobus WE, Becker LC. The functional recovery of post-ischemic myocardium requires glycolysis during early reperfusion. J Mol Cell Cardiol 1993, 25(3):261-76. 10.1006/jmcc.1993.1033, 8510169.
45. Cacicedo JM, Yagihashi N, Keaney JF, Ruderman NB, Ido Y. AMPK inhibits fatty acid-induced increases in NF-kappaB transactivation in cultured human umbilical vein endothelial cells. Biochem Biophys Res Commun 2004, 324:1204-1209. 10.1016/j.bbrc.2004.09.177, 15504342.
46. Youn JY, Wang T, Cai H. An ezrin/calpain/PI3K/AMPK/eNOSs1179 signaling cascade mediating VEGF-dependent endothelial nitric oxide production. Circ Res 2009, 104:50-59. 2720268, 19038867.
47. Xiao XF, Nikolskaya A, Jaye DA, Sigg DC. Glucagon-like peptide-1 enhances cardiac L-type Ca2+ currents via activation of the cAMP-dependent protein kinase A pathway. Cardiovasc Diabetol 2011, 10:6. 10.1186/1475-2840-10-6, 3037307, 21251280.
48. Sawe N, Steinberg G, Zhao H. Dual roles of the MAPK/ERK1/2 cell signaling pathway after stroke. J Neurosci Res 2008, 86:1659-69. 10.1002/jnr.21604, 18189318.
49. Hausenloy DJ, Lecour S, Yellon DM. Reperfusion injury salvage kinase and survivor activating factor enhancement pro-survival signaling pathways in ischemic postconditioning: two sides of the same coin. Antioxid Redox Signal 2011, 14:893-907. 10.1089/ars.2010.3360, 20615076.
50. Murphy E, Steenbergen C. Mechanisms underlying acute protection from cardiac ischemia-reperfusion injury. Physiol Rev 2008, 88:581-609. 10.1152/physrev.00024.2007, 3199571, 18391174.
51. Camina JP, Campos JF, Caminos E, Dieguez C, Casanueva FF. Obestatin mediated proliferation of human retinal pigment epithelial cells: regulatory mechanisms. J Cell Physiol 2007, 211:1-9. 10.1002/jcp.20925, 17186496.
52. Pazos Y, Alvarez CJ, Camina JP, Casanueva FF. Stimulation of extracellular signal-regulated kinases and proliferation in the human gastric cancer cells KATO-III by obestatin. Growth Factors 2008, 25:373-381.
53. Juhaszova M, Zorov DB, Yaniv Y, Nuss HB, Wang S, Sollott SJ. Role of glycogen synthase kinase-3β in cardioprotection. Circ Res 2009, 104(11):1240-1252. 10.1161/CIRCRESAHA.109.197996, 2726042, 19498210.
54. Razny U, Kiec-Wilk B, Wator L, Polus A, Dyduch G, Solnica B, Malecki M, Tomaszewska R, Cooke JP, Dembinska-Kiec A. Increased nitric oxide availability attenuates high fat diet metabolic alterations and gene expression associated with insulin resistance. Cardiovasc Diabetol 2011, 10:68. 10.1186/1475-2840-10-68, 3212914, 21781316.